|
DRUG CANDIDATES
ICA-105665
Our most advanced compound for the treatment of epilepsy and neuropathic pain is
ICA- 105665, for which we are currently conducting a multiple dose escalation study in healthy male volunteers and a cohort of epilepsy patients who are currently well controlled on other anticonvulsant medications. In addition, we have identified several lead compounds that also target specific potassium channels, which are located primarily on the
membrane of nerve cells, or neurons, present
in particular regions of the central and
peripheral nervous system. We
have retained all worldwide rights to these
compounds.
 Senicapoc for Asthma
Senicapoc is a novel small molecule
potassium channel inhibitor that we are
developing for the treatment of asthma, for
which we recently completed Phase I clinical
studies. The company expects to initiate a
Phase II clinical trial in patients with
allergen- induced asthma at selected sites in
the UK during the fall of 2008. Senicapoc
targets a particular potassium channel that
is expressed on a number of cells believed
to be important in the pathogenesis of
asthma, including various cells of the
immune and inflammatory system and airway
epithelial cells. Senicapoc is taken orally and
is being developed for once-a-day dosing.
We retain all worldwide rights to senicapoc.
|
